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Abstract
Background: Clearance of apoptotic neutrophils in the lung is an essential process to limit inflammation, since
they could become a pro-inflammatory stimulus themselves. The clearance is partially mediated by alveolar
macrophages, which phagocytose these apoptotic cells. The phagocytosis of apoptotic immune cells by
monocytes in vitro has been shown to be augmented by several constituents of pulmonary surfactant, e.g.
phospholipids and hydrophobic surfactant proteins. In this study, we assessed the influence of exogenous
poractant alfa (Curosurf®) instillation on the in vivo phagocytosis of apoptotic neutrophils by alveolar macrophages.
Methods: Poractant alfa (200 mg/kg) was instilled intratracheally in the lungs of three months old adult male C57/
Black 6 mice, followed by apoptotic neutrophil instillation. Bronchoalveloar lavage was performed and alveolar
macrophages and neutrophils were counted. Phagocytosis of apoptotic neutrophils was quantified by determining
the number of apoptotic neutrophils per alveolar macrophages.
Results: Exogenous surfactant increased the number of alveolar macrophages engulfing apoptotic neutrophils 2.6
fold. The phagocytosis of apoptotic neutrophils was increased in the presence of exogenous surfactant by a 4.7
fold increase in phagocytosed apoptotic neutrophils per alveolar macrophage.
Conclusions: We conclude that the anti-inflammatory properties of surfactant therapy may be mediated in part by
increased numbers of alveolar macrophages and increased phagocytosis of apoptotic neutrophils by alveolar
macrophages.
Keywords: Inflammation, Resolution, Anti inflammation, Drug therapy, Surfactant
Background
Apoptosis and apoptotic cell clearance are recognized as
important mechanisms in resolving inflammation, main-
taining homeostasis and tissue remodeling, e.g. during
ontogeny and repair [1]. Inefficient apoptotic cell clear-
ance results in necrosis or cytolysis, which leads to the
release of noxious cellular contents into surrounding tis-
sues and consequently tissue damage and prolonged
inflammation [1].
Efficient clearance of these apoptotic cells by phago-
cytes critically depends on a sequence of events. Firstly,
the apoptotic cells undergo changes which target them
for clearance, e.g. the loss of phospholipid asymmetry
exposes phosphatidylserine on their cell surface [2]. Sec-
ondly, these changes of the cell surface need to be
recognized by the phagocytes followed by their engulf-
ment. This can be achieved through phagocyte receptors
that interact directly with apoptotic cells and receptors
that interact through intermediate soluble bridging
molecules, like C1q and mannose-binding lectin, which
attach to the surface of the apoptotic cells [3,4].
The efficient clearance of apoptotic cells and the reso-
lution of inflammation are particularly important in
organs like the lung, which are continuously exposed to
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inadequate response to inflammatory challenges in the
lung can be observed in preterm infants. These preterm
infants suffer from lung immaturity which is intimately
linked to inflammatory events, in prenatal and immedi-
ate postnatal life [5]. These immature lungs are charac-
terized by a lower surface area for gas exchange and a
deficiency of pulmonary surfactant, which prevents
alveolar collapse at end-expiration and is important for
host defense. Together, these events trigger and contri-
bute to the development of respiratory distress syn-
drome (RDS). RDS is still a leading cause of neonatal
morbidity and mortality in the Western world. The inci-
dence of RDS is consistently rising and inversely related
to gestational age. In clinical practice, intratracheal
administration of poractant alfa (Curosurf
®)h a ss h o w n
efficacy in reducing the respiratory workload and
improving the survival and outcome for premature
infants suffering from severe RDS [6]. Poractant alfa
consists of phospholipids, mainly dipalmitoylphosphati-
dylcholine, the primary surface-active agent of natural
lung surfactant, and surfactant protein (SP)-B and SP-C,
which facilitate spreading and adsorption of the surface-
active agent at the air-alveolar interface [6]. However,
the effects of poractant alfa are not limited to the bio-
physical effects of surface tension reduction. In vitro it
has been shown to influence the phagocytic properties
of human monocytes depending on the ingested cell
type, e.g. micro-organisms or apoptotic cells [7,8]. Por-
actant alfa does however not contain the collectins SP-A
or SP-D, which are well known for their functions in
host defense and have been shown to increase the pha-
gocytosis of apoptotic neutrophils by macrophages in
vitro [9]. It was shown that severe RDS is linked to the
activation of neutrophils [10] and can be caused or sus-
tained by prolonged inflammation [5]. The observation
that poractant alfa instillation significantly reduces mor-
bidity and mortality in preterm infants suffering from
severe RDS, together with the knowledge that RDS can
be caused by prolonged inflammation, e.g. due to ineffi-
cient apoptotic cell clearance, raises the question if the
resolution of inflammation can be exclusively addressed
to SP-A and SP-D. We therefore hypothesized that the
other constituents of pulmonary surfactant, present in
poractant alfa, influence the resolution of the inflamma-
tory response by regulating the phagocytosis of apopto-
tic cells in the lung.
To test the hypothesis that increased phagocytosis of
apoptotic cells by alveolar macrophages may be part of
the anti-inflammatory effects of poractant alfa therapy
in vivo, we first studied its effect on phagocytosis of
apoptotic neutrophils by alveolar macrophages in vitro
a n dt h e ni nt h el u n g so fa d u lt mice. Poractant alfa or
saline was instilled in the lungs of three month old C57/
black mice followed by apoptotic neutrophils, i.e.
annexin V positive and propidium iodide negative cells,
or saline. The clearance of apoptotic neutrophils and
recruitment of alveolar macrophages was assessed in
bronchoalveolar lavage fluid (BALF). Furthermore, a
phagocytosis index was determined from the ratio of
alveolar macrophages participating in phagocytosis, i.e.
myeloperoxidase (MPO) positive alveolar macrophages,
and the average number of phagocytosed apoptotic neu-
trophils per alveolar macrophage, i.e. average number of
MPO-positive vesicles per alveolar macrophage.
Methods
Reagents
Antibodies and the apoptosis detection kit were pur-
chased from PharMingen (Mountain View, CA). All
other reagents were purchased from Sigma Aldrich (St.
Louis, MO).
Myeloperoxidase staining
Myeloperoxidase (MPO) activity was assayed by measur-
ing the H2O2-dependent oxidation of the chromogenic
substrate 3-Amino-9-ethylcarbazole (AEC, Sigma
Aldrich), which results in a red insoluble stain. This was
followed by a hematoxylin background stain, resulting in
an intense blue coloration of the nuclei.
In vitro phagocytosis
Alveolar macrophages were isolated from mice by
broncho-alveolar lavage [11]. Cells were washed twice
with PBS at 4°C, centrifuged for 5 min at 400 × g at 4°C,
and resuspended in culture media (DMEM) supplemen-
ted with 10% heat-inactivated fetal calf serum (Sigma
Aldrich). After incubation at 37°C for 1 h, nonadherent
cells were removed and plates were washed twice with
media. The effect of poractant alfa on phagocytosis was
tested in separate assays with apoptotic neutrophils and
fluorescein-labeled beads (size 2 μm, Molecular Probes,
E u g e n e ,O R )( s e eb e l o w ) .A l lsurfactant preparations
were tested negative for endotoxin contamination with
the Limulus amebocyte lysate assay (Sigma Aldrich). Pha-
gocytosis of apoptotic neutrophils was tested by adding 2
×1 0
5 apoptotic neutrophils to the adherent alveolar
macrophages. Poractant alfa at a final concentration of
100 μg/mL phospholipids was added 15 min before the
apoptotic neutrophils were added or the same volume of
media in control experiments [8]. The alveolar macro-
phages and apoptotic neutrophils were incubated for 15
min at 37°C, washed with cold PBS containing 0.5 mM
EDTA, and stained with MPO. Phagocytosis was evalu-
ated by counting 100 macrophages per well. Similar
experiments were performed with fluorescein-labeled
beads (Molecular Probes). Phagocytosis was evaluated on
an inverted microscope.
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Neutrophils were isolated by Percoll gradient centrifuga-
tion from the whole blood of donors. Red blood cells
were removed by osmotic lysis. Purity was assessed by
staining MPO, which is expressed in neutrophils but not
in monocytes. Apoptosis was induced in neutrophils by
UV radiation (302 nm) for 30 min. Apoptosis was con-
firmed in > 85% of all cells by flow cytometry using
fluorescently labeled annexin V to detect the phosphati-
dylserine expression on the cell surface of apoptotic
cells and a propidium iodide counterstain (PharMingen).
Preparations containing less than 8% necrotic cells were
accepted. As a positive control, cell aliquots were incu-
bated with camptothecin, a topisomerase I inhibitor that
induces apoptosis, for 3 h at 37°C. Cells were kept on
ice and analyzed on a FACSCalibur flow cytometer
(Becton Dickinson, Mountain View, CA).
Mice
The protocol was reviewed and approved by the local
authorities. Three month old adult male C57/Black 6
mice (generous gift of Prof. Ulf Rapp, MSZ University
Würzburg, Germany) were anesthetized with methoxy-
flurane and orally intubated with a 25-gauge animal-
feeding needle. Poractant alfa (Curosurf
®,g e n e r o u sg i f t
of Chiesi Farmaceutici, Parma, Italy) in a dose of 200
mg/kg or the equivalent volume of saline (0.9% w/v
NaCl) was instilled. Subsequently, 10
6 apoptotic neutro-
phils suspended in 100 μl of saline (only saline for con-
trols) were injected via tracheal intubation in each
mouse (n = 11 per group and timepoint).
The fate of the instilled apoptotic neutrophils was
assessed after 15 min or 30 min respectively. A bronch-
oalveloar lavage was performed after the indicated time
interval. Mice were deeply anesthetized with intraperito-
neal pentobarbital sodium administration and exsangui-
nated by cutting the distal aorta (11). The thorax was
opened, and a 20-gauge blunt needle was tied into the
proximal trachea for alveolar lavage. Lungs were washed
with 1 ml of 0.9% saline, which was infused and with-
drawn by syringe three times. This lavage procedure was
performed five times for each animal and pooled for
analysis. Lavage fluid volumes were recorded and the
lavages were immediately centrifuged for 15 min at 500
× g to spin down the cells. The pellets were resuspended
in a defined volume of PBS and the cells were counted
after staining with trypan blue (Scientific Products,
McGaw Park, IL). Cytospins were stained for MPO
activity to identify phagocytosed apoptotic neutrophils.
Phagocytosis of apoptotic neutrophils was quantified by
counting the number of MPO-positive vesicles in alveo-
lar macrophages and determining the percentage of
MPO-positive alveolar macrophages. A phagocytic index
was calculated by multiplying the percentage of MPO-
positive macrophages by the average number of phago-
cytosed vesicles.
Data analysis
R e s u l t sa r eg i v e na sm e a n±S E M. Physiologic variables
were analyzed using a two tailed t-test (for 2 groups) or
one-way ANOVA with a Bonferroni post test (more
than 2 groups). A p-value < 0.05 was considered signifi-
cant. All statistical analyses were performed using the
statistical software GraphPad Prism 5.0.
Results
In vitro phagocytosis
Alveolar macrophages increased phagocytosis of apoptotic
neutrophils in vitro. The phagocytosis index increased
from 20 ± 6 in control alveolar macrophages to 132 ± 39
in the poractant alfa incubated alveolar macrophages (p <
0.05). No effect of poractant alfa was detected in alveolar
macrophages that were incubated with fluorescein-labeled
beads. The phagocytosis index was 43 ± 7 without porac-
tant alfa and 48 ± 9 with poractant alfa (not significant).
Apoptotic neutrophils in BALF
A time course experiment (Figure 1a) revealed that the
number of apoptotic neutrophils in BALF 15 minutes
after instillation was elevated from 0.8 ± 0.7 × 10
4/kg
body weight (BW) in saline controls to 7.8 ± 0.8 × 10
4/
kg BW (p < 0.05) in treated mice. This marked increase
in the number of apoptotic neutrophils dropped to
background levels as soon as 30 minutes after instilla-
tion. The effect of exogenous surfactant instillation was
therefore assessed 15 minutes after the instillation of
apoptotic neutrophils. Poractant alfa reduced the num-
ber of apoptotic neutrophils detected in BALF from 7.9
±1 . 1×1 0
4/kg BW in saline controls to 3.1 ± 0.8 × 10
4/
kg BW (p < 0.05) in treated mice (Figure 1b)
Alveolar macrophages in BALF
The number of alveolar macrophages recovered from
BALF in mice undergoing no intervention was 0.43 ±
0.06 × 10
6/kg BW, which was unchanged by saline (0.52
±0 . 0 9×1 0
6/kg BW) or poractant alfa (0.62 ± 0.22 ×
10
6/kg BW) instillation (Figure 2). After instillation of
apoptotic neutrophils the number of alveolar macro-
phages increased to 1.49 ± 0.16 × 10
6/kg BW (p < 0.05).
Nor the treatment with saline (1.62 ± 0.17 × 10
6/kg
BW) or poractant alfa (1.76 ± 0.19 × 10
6/kg BW) had
any influence on the number of alveolar macrophages
after apoptotic neutrophil instillation.
Phagocytosis by alveolar macrophages
The number of macrophages ingesting apoptotic neutro-
phils and the amount of apoptotic neutrophils phagocy-
tosed by each macrophage was assessed by MPO staining
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treatment with poractant alfa increased the number of
MPO-positive macrophages to 8.2 ± 0.8 × 10
5/kg BW (p <
0.05) compared to saline treated controls (3.2 ± 1.1 × 10
5/
kg BW, Figure 3b). The phagocytosis index (Figure 3c)
after instillation of apoptotic neutrophils increased from
19 ± 5 after saline injection to 70 ± 11 after poractant alfa
instillation (p < 0.05 vs saline injection).
Discussion
In this paper we demonstrated for the first time that
poractant alfa, an exogenous porcine derived lung sur-
factant, increased the clearance of apoptotic neutrophils
in vivo. This was the result of both an increased number
of alveolar macrophages engulfing apoptotic neutrophils
and a higher number of phagocytosed apoptotic neutro-
phils per alveolar macrophage.
Figure 1 A) Time course experiment showing the number of apoptotic neutrophils per kilogram body weight (BW) in BALF 15 or 30
minutes after intratracheal instillation of apoptotic neutrophils (+) or an equivalent volume of saline (-). B) The number of apoptotic
neutrophils per kilogram body weight in BALF 15 minutes after administering 10
6 apoptotic neutrophils and subsequently instilling poractant
alfa or an equivalent volume of saline. Results (n = 11 animals per group) are shown as mean ± SEM. Significant differences (p < 0.05) are
marked by *.
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vital during development, maintaining homeostasis and
resolving inflammation in the lung. These processes are
all involved in the development and resolution of RDS.
Nowadays exogenous surfactant (e.g. poractant alfa)
replacement therapy and ventilation are standard of care
for infants suffering from severe RDS in the Western
world. The reduction of surface tension and workload
through surfactant therapy greatly reduces the morbidity
and mortality [6]. However, the close association of RDS
with inflammation suggests the beneficial modes of
action of surfactant go beyond the reduction of work-
load. Indeed, there is a vast array of research on the
immunomodulatory functions of surfactant [12]. Several
studies have reported immunomodulatory functions of
poractant alfa or its lipid constituents on various levels
of the inflammatory response. For instance, it was
shown to impair the phagocytosis of microorganisms by
monocytes [7], impair the respiratory burst of mono-
cytes and neutrophils exposed to inflammatory stimuli
[13,14] and modulate the release of pro- and anti-
inflammatory cytokines [7,15-19]. The phagocytosis of
apoptotic cells under influence of poractant alfa has also
been studied in vitro [8]. This study revealed that porac-
tant alfa enhanced the phagocytosis of apoptotic cells by
monocytes.
We have now tested this observation in adult mice in
vivo to confirm our in vitro findings. Specifically, this
study provides evidence that apoptotic neutrophils are
cleared efficiently by recruiting alveolar macrophages as
soon as 15 minutes after instillation. This fast response
indicates these macrophages resided in close apposition
to the alveolar unit, e.g. the interstitial space. In the
control animals the number of apoptotic neutrophils
returned to background levels within 30 minutes. Porac-
tant alfa enhanced the clearance of apoptotic neutro-
phils, significantly lowering their levels within 15
minutes, without altering the amount of recruited
macrophages. MPO staining of cells in BALF revealed
that the enhanced clearance of apoptotic neutrophils
was the result of an increased ratio of macrophages par-
ticipating in the clearance (MPO-positive macrophages)
and an elevated activity of these macrophages (phagocy-
tosis index). This ultimately resulted in a vast reduction
of the number of apoptotic neutrophils in the lungs
resolving the inflammation [20-22].
The experiments showed that only a low percentage of
instilled apoptotic neutrophils (~3%) could be recovered
in bronchoalveolar lavage fluid and in the mobilized
alveolar macrophages. This is partially explained by the
low recovery of alveolar macrophages by bronchoalveo-
lar lavage techniques that can only mobilize approxi-
mately 30% of the alveolar macrophages [23]. Besides
the low rate of recovery of alveolar macrophages as an
inherent technical limitation, the kinetics of alveolar
macrophages in the trafficking to and from the blood
vessels and interstitium cannot be estimated in this
model. Mechanisms involved in the observed effects
remain elusive since most studies on the immunomodu-
latory functions of surfactant, including the phagocytosis
of apoptotic cells, investigated the role of the hydrophi-
lic surfactant proteins SP-A and SP-D, which are not
present in poractant alfa. A comprehensive study by
Gardai et al. [24] shed light on the apparent conflicting
data from some of these diverse studies on these immu-
nomodulatory properties of SP-A and SP-D, by pointing
out that the various domains of these proteins have
opposing functions. They revealed the collagenous tail
domain was responsible for phagocytosis of pathogens
and enhancing the production of pro-inflammatory
mediators by alveolar macrophages, while the head
domain, which recognizes and opsonizes pathogens,
inhibited the production of these mediators. The last
decade the involvement of collectins SP-A and SP-D in
the clearance of apoptotic neutrophils has also gained
attention, but has to date not been fully elucidated [25].
These studies have however shown that for the clear-
ance of apoptotic cells the various domains of these pro-
teins seem to fulfill different roles. Schagat et al.
revealed that the lectin domain was not involved in the
phagocytosis of apoptotic neutrophils, but the carbohy-
drate moieties of SP-A were [25]. However, it appeared
that these were involved in binding alveolar macro-
phages rather than apoptotic neutrophils. An involve-
ment of the lipid binding capabilities of SP-A in
recognizing apoptotic cells could not be ruled out. Simi-
lar to Gardai et al. [24], another study showed that
Figure 2 The number of alveolar macrophages per kilogram of
body weight in BALF of mice instilled with 10
6 apoptotic
neutrophils or the equivalent volume of saline, receiving no
treatment, saline or poractant alfa. Results (n = 11 animals per
group) are shown as mean ± SEM. Significant differences (p < 0.05)
are marked by *.
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Page 5 of 8Figure 3 A) Myeloperoxidase (MPO) staining of neutrophils before induction of apoptosis (left panel), alveolar macrophages in BALF
from mice that received saline instillation (middle panel) and apoptotic neutrophils phagocytosed by alveolar macrophages in BALF
from mice that received apoptotic neutrophils instillation (right panel). B) Number of MPO-positive alveolar macrophages per kilogram of
body weight in BALF of mice instilled with 10
6 apoptotic neutrophils, receiving saline (-) or poractant alfa (+) treatment. C) Phagocytosis index of
apoptotic neutrophils ingestion by alveolar macrophage in BALF of mice instilled with 10
6 apoptotic neutrophils, receiving saline (-) or poractant
alfa treatment (+). The phagocytosis index was calculated by multiplying the percentage of MPO-positive alveolar macrophages with the average
number of apoptotic neutrophils ingested per MPO-positive alveolar macrophage. Results (n = 11 animals per group) are shown as mean ± SEM.
Significant differences (p < 0.05) are marked by *.
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macrophages through their collagenous domain by enga-
ging with the CD91/calreticulin receptor complex [26].
However, these effects could not be completely inhibited
by blocking CD91/calreticulin, which could indicate
redundant receptors and mechanisms involved in apop-
totic cell clearance. Overall, this redundancy in recep-
tors, mechanisms and bridging molecules hampers the
unambiguous investigation of events in vivo. Addition-
ally, recent evidence suggests that these collectins differ-
ently engage binding with viable, early and late
apoptotic cells [27-29]. This is further complicated by
the fact that divergent results have been observed for
resident and recruited alveolar macrophages [30]. A
more recent study by Janssen et al. [31] shed some light
on some of these divergent results. They showed that
the removal of alveolar macrophages improved the pha-
gocytic activity to levels observed for macrophages of
other origin and that the exposure to SP-A and SP-D
reduced their phagocytic activity. They hypothesized
that a tonic interaction of SP-A and SP-D with SIRPa
suppressed alveolar macrophage phagocytic function.
This could also explain our observations, that an instilla-
tion of poractant alfa improves phagocytosis, i.e. the
lipids in surfactant compete with SIRPa in binding the
head domain of these collectins, thereby lifting their
suppressive effects on phagocyte function. However, the
suggested mechanisms require further investigation, for
instance by evaluating the influence of supplementing
the surfactant preparations with SP-A and/or SP-D in
the future.
One limitation of our study was that adult animals
were used as a model, while surfactant administration is
currently limited to the neonatal period. However, this
was necessary since we demonstrated earlier that the
total number of alveolar macrophages is too small in
the premature lung for current detection methods [32].
Alveolar macrophages differentiate in the fetal lung late
in gestation from blood derived monocytes [33]. The
induction of alveolar macrophages can be induced in
utero by proinflammatory stimuli causing chorioamnio-
nitis [32], however these experiments could not be per-
formed in preterm mice.
In summary, exogenous porcine derived lung surfac-
tant poractant alfa increased the phagocytosis and clear-
ance of apoptotic neutrophils by alveolar macrophages
in vivo. Surfactant therapy may therefore possess anti-
inflammatory properties in vivo, by enhancing the reso-
lution of the inflammation and ultimately protecting the
pulmonary tissue from damaging inflammatory
responses. The extrapolation of these effects to imma-
ture lungs needs to be done with caution. We have
however previously shown in vitro that similar effects
could be observed with blood derived monocytes, which
may be the prevailing cell type in the immature lung
[32].
Conclusion
This study shows that exogenous surfactant therapy may
possess anti-inflammatory properties in vivo. The anti-
inflammatory properties of surfactant therapy were in
part mediated by increased numbers of alveolar macro-
phages and increased phagocytosis of apoptotic neutro-
phils by alveolar macrophages.
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